# Deliverables Summary

## Task
Draft an OFAC specific license application package and an internal issues memo from the attached source documents concerning Meridian Biotech Solutions, Inc.'s proposed export of cancer diagnostic supplies and remote training to Damascus Central University Hospital (DCUH), Syria.

## Source documents reviewed (all eight)
1. Client email — transaction summary (June 24, 2024)
2. Compliance screening memo (Peggy Dunleavy, June 10, 2024)
3. DCUH purchase order PO-DCUH-2024-0743 (June 17, 2024)
4. Graystone compliance audit executive summary (Sept 29, 2023)
5. Prior OFAC specific license SYR-2021-384712 (Sept 14, 2021)
6. Combined product technical data sheets (TDS-2024-0347, March 15, 2024)
7. Pinnacle shipping & logistics plan (June 25, 2024)
8. WHO Syria needs assessment, Section 4.7 (January 2024)

## Deliverables (in `output/`)
- **`ofac-specific-license-application.docx`** — A complete, file-ready specific license application package addressed to OFAC's Licensing Division under 31 C.F.R. Part 542 / E.O. 13582. Contains a transmittal letter and Parts I–XV covering: applicant information; legal authority; transaction description; parties and screening results; end-user/end-use; products and EAR99 classification; five-leg shipping route; restructured payment (away from the SDN-listed Central Bank of Calverley); full disclosure of the two SDN-related findings (30% SDN shareholder of the customs agent; SDN remitting bank) and the restructuring to eliminate them; compliance program (including the three Graystone audit findings and their status); prior license history; humanitarian justification (WHO assessment); requested license terms/conditions/reporting commitments; certifications and signature; and an exhibit list (Exhibits A–I).

- **`issues-memorandum.docx`** — A privileged internal attorney work-product memo from Ashford & Whitmore LLP enumerating **31 distinct issues**, each with analysis and a recommendation, organized into seven categories: (A) SDN/restricted-party issues; (B) transaction structure and payment; (C) export control and technology transfer; (D) logistics and end-use; (E) compliance program and process; (F) substantive merits/favorable factors; and (G) client-communication/scope-correction. Closes with a recommended application strategy and a nine-item open-items/next-steps list.

## Key analytical points captured
- Two SDN exposures the client's email understated: Samir Daoud Khoury (30% shareholder of ARMPC, designated Apr 15, 2024) and the Central Bank of Calverley (SDN since Aug 10, 2011).
- Governmental end-user (DCUH / Syrian Ministry of Health) under E.O. 13582.
- Restructuring strategy: non-SDN Syrian commercial bank for payment (mirroring the prior license) and removal of ARMPC in favor of a screened replacement agent.
- Technology-transfer/deemed-export considerations from the remote training (schematics, 287-page Software Reference Manual) and firmware scope limitation (v4.2.1 only; no OTA updates).
- Cold-chain integrity, shelf-life margin, transshipment/re-export via Turkey and Bab al-Hawa, end-use monitoring plan (Graystone Finding 2), re-screening cadence, license-term/timing, reporting conditions, and the "EAR99 does not obviate OFAC authorization" correction.

## Validation
Both `.docx` files passed `skills/docx/scripts/validate.py` (ZIP integrity, XML well-formedness, content-type registration, relationship consistency).

## Completeness audit (performed before finishing)
A full re-read of all eight source documents and a content-level cross-check of both deliverables (69-point verification script) confirmed coverage. The audit found and corrected the following:

1. **Fabricated citation removed.** The application Part II.2 had cited "31 C.F.R. § 542.508" — a specific section number not supported by any source document (which cite only 31 C.F.R. Part 542 generally). Replaced with the general licensing authority of 31 C.F.R. Part 542 and E.O. 13582. All remaining citations (31 C.F.R. § 501.601; 15 C.F.R. Parts 730–774; 50 U.S.C. 1701–1706) are source-supported.

2. **Four omitted issues added** to the issues memorandum as a new Category H (Issues 32–35), each with its own explicit treatment, plus corresponding open-items entries and an executive-summary reference:
   - **Issue 32 — General license vs. specific license determination** (the compliance memo Note 1 expressly asked counsel to determine whether a general or specific license is required). Also addressed in application Part II.4.
   - **Issue 33 — Compliance Department "Moderate-to-High" overall risk assessment** (cited in the screening memo's Overall Risk Assessment section).
   - **Issue 34 — Product-description discrepancy** (the screening memo describes the RX-700 as a "human serum and plasma" assay; the datasheet and PO describe it as IHC staining of FFPE tissue biopsies — different sample matrices). The application uses the accurate FFPE description.
   - **Issue 35 — Remote training connectivity/on-site equipment prerequisites** (datasheet requires ≥10 Mbps internet, webcam workstation, and on-site CalibPro + 2 RX-700 kits; unconfirmed given Syria's degraded infrastructure).

The issues memorandum now enumerates **35 distinct issues** (Issues 1–35), each individually treated.